Budget Impact Analysis of Immunotherapy as Second-line Treatment of NSCLC at MX's National Institute of Cancer

Ramirez Tirado LA., Barron F., Zatarain Barron L., Peralta Alvarez MP., Meneses-Garcia AA., Ruiz-Godoy LM., De La Garza Salazar J., Palafox Torres DI., Chavez Millan MF., Paladio Hernandez JA., Cardona AF., Arrieta O.

DOI

10.1016/j.jtho.2019.09.191

Type

Conference paper

Publication Date

2019-01-01T00:00:00+00:00

Volume

14

Pages

S1196 - S1196

Keywords

Pharmacoeconomy, Immunotherapy, Costs, Pembrolizumab

Permalink More information Close